Letter RE: Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study
We added a comment to the the article by Kim et al.. We first described how the hazard function and commonly used survival function act complementary, although these two functions are mathematically equivalent. Then, we pointed out two notable findings of the present article: 1) a recurrence by metastasis is presumed to occurred constantly at an annualized incidence of 4%-10% until 6 postoperative years; and 2) the annualized recurrence rates between the 5th and 10th postoperative years were between 3%-10% in cirrhotic patients and this figure was comparable to or even lower than the reported annual incidence of HCC in ...
Source: Liver Cancer - May 13, 2022 Category: Cancer & Oncology Source Type: research

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Non-inflamed Subclass
NA (Source: Liver Cancer)
Source: Liver Cancer - May 10, 2022 Category: Cancer & Oncology Source Type: research

Erratum
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 9, 2022 Category: Cancer & Oncology Source Type: research

Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment
Hepatocellular carcinoma is one of the leading causes of cancer-related death not only in Japan, but also worldwide. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver cancer in Japan and implantation of a catheter system (called a port system) in the body is a treatment method that has evolved mainly in Japan. The Guideline Committee of the Japanese Society of Interventional Radiology and the Japanese Society of Implantable Port Assisted Treatment jointly developed clinical practice guidelines for HAIC with a port system to ensure its appropria...
Source: Liver Cancer - May 5, 2022 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2022;11:184 –184 (Source: Liver Cancer)
Source: Liver Cancer - April 11, 2022 Category: Cancer & Oncology Source Type: research

Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR imaging Features and its Prognostic Value
Conclusions: Preoperative liver MRI may he lp predict the pathologic subtype of iCCAs as either the SD-type or LD-type, allowing preoperative identification of patients with poorer survival outcomes. (Source: Liver Cancer)
Source: Liver Cancer - March 30, 2022 Category: Cancer & Oncology Source Type: research

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Futu...
Source: Liver Cancer - March 17, 2022 Category: Cancer & Oncology Source Type: research

Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumour thrombus in China (2021 edition)
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the Guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available especially for the advent of new targeted drugs and immune checkpoint inhibitor (ICIs) which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer (CALC) and Chinese Medical Doctor Association(CMDA) revised the 2018 version of guideline to adapt to the development of PVTT t...
Source: Liver Cancer - March 17, 2022 Category: Cancer & Oncology Source Type: research

Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study
Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective analysis included 142 consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who received lenvatinib alone as first-line treatment from 15 Chinese academic centers from Nov 2018 to Nov 2019. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) evaluated by mRECIST criteria, and s...
Source: Liver Cancer - March 9, 2022 Category: Cancer & Oncology Source Type: research

Liver Cancer Study Group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma
This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, high incidence of ICC has been reported in East and Southeast Asian countries and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesi...
Source: Liver Cancer - February 23, 2022 Category: Cancer & Oncology Source Type: research

Management of systemic therapies and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma based on sarcopenia assessment
Background: Sarcopenia, defined as the loss of skeletal muscle mass, physical performance, and strength, has been associated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients treated with several therapies. As systemic therapies, including molecular targeted agents, have a strong impact on sarcopenia, we aimed to review the impact of sarcopenia in patients receiving systemic therapies, especially sorafenib and hepatic arterial infusion chemotherapy (HAIC). Summary: Several studies have demonstrated that sarcopenia is associated with poor clinical outcomes in patients receiving sorafenib or lenvatinib,...
Source: Liver Cancer - February 22, 2022 Category: Cancer & Oncology Source Type: research

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
N/A (Source: Liver Cancer)
Source: Liver Cancer - February 18, 2022 Category: Cancer & Oncology Source Type: research

Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy
In this study, at eight weeks after resumption of LEN after initial TACE, "deep response" was defined as achieving CR or PR on mRECIST, and at least a 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters as the reference. Results: The OS and PFS in the LEN-TACE group were significantly higher than those in the LEN monotherapy group (P = 0.002 and P = 0.037, respectively). The incidence of AEs related to LEN was not significantly different between the two groups. In LEN-TACE sequential therapy, the objective response rate was 61.9%, and the disease control rate was 74.6%, according to t...
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
Conclusion: Based on a favorable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200 mg BID. Studies to evaluate the antitumor activity of GNS561 in hepatocarcinoma cells and intrahepatic cholangiocarcinoma are to follow NCT 03316222. (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers
Conclusion - Based on a favourable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200mg BID. Studies to evaluate the antitumor activity of GNS561 in HCC and iCCA are to follow. NCT 03316222 (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research